Special Drug Use Surveillance of ADZYNMA Intravenous 1500 (All-Case Investigation).

This article discusses a clinical trial in Japan, NCT06441578, which is investigating the use of recombinant ADAMTS13 in the treatment and prevention of congenital thrombotic thrombocytopenic purpura (cTTP). The study sponsor will not administer treatment but will provide guidance on data collection. The main goals of the study are to assess any side effects associated with recombinant ADAMTS13 and to determine its effectiveness in improving or preventing cTTP. Participants with cTTP will receive intravenous injections of recombinant ADAMTS13 as per their clinic's standard practice, and side effects will be monitored for 18 months. [Extracted from the article]